Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Crohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab.

Next Previous
Trial Profile

Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Crohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use

Most Recent Events

  • 03 Jan 2023 Status changed from recruiting to completed.
  • 04 Dec 2014 Planned End Date changed from 1 Jul 2013 to 1 Jul 2015 as reported by ClinicalTrials.gov.
  • 18 Nov 2011 Additional trial identifier 2010-566 identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top